Literature DB >> 16698954

Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.

Sylvia Stadlmann1, Uwe Gueth, Edward Wight, Leoni A Kunz-Schughart, Arndt Hartmann, Gad Singer.   

Abstract

AIM: Peroxisome proliferator-activated receptor gamma (PPARgamma) has emerged as a potential therapeutic target in several types of cancer. In ovarian carcinomas, limited and conflicting data on PPARgamma protein expression have been reported.
METHODS: The immunoexpression of PPARgamma and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy.
RESULTS: PPARgamma expression was observed in 29% of primary and recurrent carcinomas. In the recurrent tumours, PPARgamma expression inversely correlated with COX2 overexpression in both chemosensitive (p = 0.02) and chemoresistant (p = 0.04) carcinomas.
CONCLUSIONS: The data indicate that PPARgamma may represent a potential target for second-line treatment in ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698954      PMCID: PMC1860580          DOI: 10.1136/jcp.2005.035717

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  37 in total

1.  Feedback control of cyclooxygenase-2 expression through PPARgamma.

Authors:  H Inoue; T Tanabe; K Umesono
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

2.  Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells.

Authors:  H Ikawa; H Kameda; H Kamitani; S J Baek; J B Nixon; L C Hsi; T E Eling
Journal:  Exp Cell Res       Date:  2001-07-01       Impact factor: 3.905

3.  Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.

Authors:  Y Matsumoto; O Ishiko; M Deguchi; E Nakagawa; S Ogita
Journal:  Int J Mol Med       Date:  2001-07       Impact factor: 4.101

4.  PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.

Authors:  Nomelí P Núñez; Huaitian Liu; Gary G Meadows
Journal:  Cancer Lett       Date:  2005-06-23       Impact factor: 8.679

5.  Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells.

Authors:  W L Yang; H Frucht
Journal:  Carcinogenesis       Date:  2001-09       Impact factor: 4.944

Review 6.  Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).

Authors:  M B Sporn; N Suh; D J Mangelsdorf
Journal:  Trends Mol Med       Date:  2001-09       Impact factor: 11.951

7.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

8.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

Authors:  Carsten Denkert; Martin Köbel; Sören Pest; Ines Koch; Stefan Berger; Michael Schwabe; Antje Siegert; Angela Reles; Bernd Klosterhalfen; Steffen Hauptmann
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

9.  Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists.

Authors:  H Sato; S Ishihara; K Kawashima; N Moriyama; H Suetsugu; H Kazumori; T Okuyama; M A Rumi; R Fukuda; N Nagasue; Y Kinoshita
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma.

Authors:  M A Rumi; H Sato; S Ishihara; K Kawashima; S Hamamoto; H Kazumori; T Okuyama; R Fukuda; N Nagasue; Y Kinoshita
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

View more
  7 in total

1.  Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression.

Authors:  Zhen-Zhong Feng; Jia-Wei Chen; Zhao-Rui Yang; Guang-Zhong Lu; Zhao-Gen Cai
Journal:  Med Oncol       Date:  2010-12-22       Impact factor: 3.064

2.  High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.

Authors:  Raoul A Droeser; Uwe Güth; Serenella Eppenberger-Castori; Sylvia Stadlmann; Christian Hirt; Luigi Terracciano; Gad Singer
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-28       Impact factor: 4.553

3.  Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Authors:  Anne-Katrin Zimmermann; Jochen Imig; Agnes Klar; Christoph Renner; Dimitri Korol; Daniel Fink; Sylvia Stadlmann; Gad Singer; Alexander Knuth; Holger Moch; Rosmarie Caduff
Journal:  Virchows Arch       Date:  2013-03-26       Impact factor: 4.064

4.  MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.

Authors:  Raoul A Droeser; Robert Mechera; Silvio Däster; Benjamin Weixler; Marko Kraljević; Tarik Delko; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Gad Singer
Journal:  BMC Cancer       Date:  2016-08-17       Impact factor: 4.430

5.  Possible role of PPARγ in the negative regulation of ovulatory cascade and luteal development in rats.

Authors:  Ryohei Funahashi; Takanobu Sakamoto; Norihito Taguchi; Ryosuke Naiki; Ryota Terashima; Mitsumori Kawaminami; Shiro Kurusu
Journal:  J Vet Med Sci       Date:  2017-05-19       Impact factor: 1.267

6.  High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.

Authors:  Michaela Ramser; Simone Eichelberger; Silvio Däster; Benjamin Weixler; Marko Kraljević; Robert Mechera; Athanasios Tampakis; Tarik Delko; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Raoul A Droeser; Gad Singer
Journal:  BMC Cancer       Date:  2018-04-16       Impact factor: 4.430

7.  Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma.

Authors:  Stefanie Meyer; Thomas Vogt; Michael Landthaler; Anna Berand; Albrecht Reichle; Frauke Bataille; Andreas H Marx; Anne Menz; Arndt Hartmann; Leoni A Kunz-Schughart; Peter J Wild
Journal:  PPAR Res       Date:  2009-07-20       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.